Platelet rich plasma formulations and use thereof

Abstract

Compositions for platelet rich plasma (PRP), depleted in neutrophils, are provided. Generally, these compositions comprise a higher concentration of platelets, lymphocytes and monocytes than whole blood with selective depletion of neutrophils to a concentration of less than about 5000/μl. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The PRP composition may be delivered in conjunction with reperfusion therapy.

1 .- 21 . (canceled) 
     
     
         22 . A composition for treating damaged connective tissue comprising:
 platelets in a concentration of about 500,000/uL to about 7,000,000/uL; and   neutrophils in a concentration eliminated to about 60,000 per microliter.   
     
     
         23 . The composition of  claim 22 , wherein the composition does not include an exogenous activator. 
     
     
         24 . The composition of  claim 22 , wherein the concentration of neutrophils is about 1000/μl to about 60,000/μl. 
     
     
         25 . The composition of  claim 22 , wherein the concentration of platelets is between about 600,000 platelets/μl and about 5,000,000 platelets/μl. 
     
     
         26 . The composition of  claim 22 , wherein the concentration of platelets is between about 700,000 platelets/μl and about 2,500,000 platelets/μl. 
     
     
         27 . The composition of  claim 22 , wherein the concentration of platelets is between about 900,000 platelets/μl and about 1,500,000 platelets/μl. 
     
     
         28 . A composition for treating damaged connective tissue comprising:
 platelets in a concentration of about 500,000/uL to about 7,000,000/uL; and   monocytes in a concentration less than 1,000/uL to 5,000/uL.   
     
     
         29 . The composition of  claim 28 , wherein the monocytes in a concentration less than 1,000/uL to 4,500/uL. 
     
     
         30 . The composition of  claim 28 , wherein the composition does not include an exogenous activator. 
     
     
         31 . The composition of  claim 28 , wherein the composition further comprises neutrophils in a concentration of about 5,000/μl to about 20,000/μl. 
     
     
         32 . The composition of  claim 28 , wherein the composition further comprises neutrophils in a concentration of about 20,000/μl to about 40,000/μl. 
     
     
         33 . The composition of  claim 28 , wherein the composition further comprises neutrophils in a concentration of about 40,000/μl to about 60,000/μl. 
     
     
         34 . A composition for treating damaged connective tissue comprising:
 platelets in a concentration of about 500,000/uL to about 7,000,000/uL; and   lymphocytes in a concentration of about 2,000/uL to about 20,000/uL.   
     
     
         35 . The composition of  claim 34 , wherein the composition does not include an exogenous activator. 
     
     
         36 . The composition of  claim 34 , wherein the composition further comprises neutrophils in a concentration of about 5,000/μl to about 20,000/μl. 
     
     
         37 . The composition of  claim 34 , wherein the composition further comprises neutrophils in a concentration of about 20,000/μl to about 40,000/μl. 
     
     
         38 . The composition of  claim 34 , wherein the composition further comprises neutrophils in a concentration of about 40,000/μl to about 60,000/μl.